Shire Re-petitions On Mesalamine, Says FDA Flunked Bibliography
This article was originally published in The Pink Sheet Daily
Executive Summary
Appeal of the agency's partial rejection of the company's citizen petition on standards for mesalamine ANDAs argues that FDA needs to provide more scientific backing for its decision to allow approval based on PK studies.